Lowering inflammation to address residual CV risk

Lowering inflammation to address residual CV risk
3' education - Mar. 17, 2017 - Dr. Paul M. Ridker - Boston, MA, USA
  • Overview

    Dr. Paul M. Ridker explains the concept of residual inflammatory risk. Currently, trials are investigating whether lowering inflammatory components might reduce CV event rates.

  • Educational information

    This video was recorded during ACC 2017, Washington DC, USA. PACE-cme did not receive financial support for the production of this video.

    The educational content reflects the personal opinion of the expert.

  • Disclosures

    Dr. Paul M. Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital. A cardiovascular medicine specialist, he is also the Eugene Braunwald Professor of Medicine at Harvard School of Medicine.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free